Plasma cell myeloma refractory
RecruitingStudy Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
- Disease:Plasma cell myeloma refractory
- Substances:BortezomibDexamethasone+2
Italy- Participants:18–64 years · 65+ years
- Substances:Bortezomib
- Sponsor:Celgene Corp.













